-
Loading metrics
Open Access
Peer-reviewed
Research Article
Early Detection of Erlotinib Treatment Response in NSCLC by 3′-Deoxy-3′-[18F]-Fluoro-L-Thymidine ([18F]FLT) Positron Emission Tomography (PET)
-
Roland T. Ullrich,
Affiliations Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch-Laboratories of the Max Planck Society, Medical Faculty of the University of Cologne, Cologne, Germany, Center for Molecular Medicine Cologne (CMMC), Cologne, Germany
⨯ -
Thomas Zander,
Affiliation Department I of Internal Medicine and Center of Integrated Oncology Köln – Bonn, University of Cologne, Cologne, Germany
⨯ -
Bernd Neumaier,
Affiliation Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch-Laboratories of the Max Planck Society, Medical Faculty of the University of Cologne, Cologne, Germany
⨯ -
Mirjam Koker,
Affiliation Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch-Laboratories of the Max Planck Society, Medical Faculty of the University of Cologne, Cologne, Germany
⨯ -
Takeshi Shimamura,
Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Yannic Waerzeggers,
Affiliation Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch-Laboratories of the Max Planck Society, Medical Faculty of the University of Cologne, Cologne, Germany
⨯ -
Christa L. Borgman,
Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Samir Tawadros,
Affiliation Department I of Internal Medicine and Center of Integrated Oncology Köln – Bonn, University of Cologne, Cologne, Germany
⨯ -
Hongfeng Li,
Affiliation Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch-Laboratories of the Max Planck Society, Medical Faculty of the University of Cologne, Cologne, Germany
⨯ -
Martin L. Sos,
Affiliation Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch-Laboratories of the Max Planck Society, Medical Faculty of the University of Cologne, Cologne, Germany
⨯ -
Heiko Backes,
Affiliation Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch-Laboratories of the Max Planck Society, Medical Faculty of the University of Cologne, Cologne, Germany
⨯ -
Geoffrey I. Shapiro,
Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Jürgen Wolf,
Affiliation Department I of Internal Medicine and Center of Integrated Oncology Köln – Bonn, University of Cologne, Cologne, Germany
⨯ -
Andreas H. Jacobs,
Affiliations Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch-Laboratories of the Max Planck Society, Medical Faculty of the University of Cologne, Cologne, Germany, Center for Molecular Medicine Cologne (CMMC), Cologne, Germany, Klinikum Fulda, Fulda, Germany
⨯ -
Roman K. Thomas ,
Contributed equally to this work with: Roman K. Thomas, Alexandra Winkeler
* E-mail: nini@nf.mpg.de
Affiliations Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch-Laboratories of the Max Planck Society, Medical Faculty of the University of Cologne, Cologne, Germany, Department I of Internal Medicine and Center of Integrated Oncology Köln – Bonn, University of Cologne, Cologne, Germany, Chemical Genomics Center of the Max Planck Society, Dortmund, Germany
⨯ - [ ... ],
-
Alexandra Winkeler
Contributed equally to this work with: Roman K. Thomas, Alexandra Winkeler
Affiliations Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch-Laboratories of the Max Planck Society, Medical Faculty of the University of Cologne, Cologne, Germany, Center for Molecular Medicine Cologne (CMMC), Cologne, Germany
⨯ - [ view all ]
- [ view less ]
Early Detection of Erlotinib Treatment Response in NSCLC by 3′-Deoxy-3′-[18F]-Fluoro-L-Thymidine ([18F]FLT) Positron Emission Tomography (PET)
- Roland T. Ullrich,
- Thomas Zander,
- Bernd Neumaier,
- Mirjam Koker,
- Takeshi Shimamura,
- Yannic Waerzeggers,
- Christa L. Borgman,
- Samir Tawadros,
- Hongfeng Li,
- Martin L. Sos
- Published: December 12, 2008
- https://doi.org/10.1371/journal.pone.0003908